Breaking News
0

Top Stock Reports For Johnson & Johnson, Boeing & Pfizer

By Zacks Investment ResearchOct 17, 2019 04:00AM ET
www.investing.com/analysis/top-stock-reports-for-johnson--johnson-boeing--pfizer-200474904
Top Stock Reports For Johnson & Johnson, Boeing & Pfizer
By Zacks Investment Research   |  Oct 17, 2019 04:00AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Thursday, October 17, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (NYSE:JNJ) (JNJ), Boeing (BA) and Pfizer (PFE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date (4.7% vs. 0.3%). The Zacks analyst thinks that J&J’s Pharma unit is faced with significant generic/biosimilar headwinds in 2019.

However, J&J’s Pharma unit is performing above-market levels supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions. It has gained FDA approval for two new drugs in 2019, Balversa and Spravato. J&J’s shares have outperformed the industry this year.

Headwinds like biosimilar/generic competition and pricing pressure remain. J&J faces numerous lawsuits, which allege personal injuries to patients caused by the use of its products.

(You can read the full research report on Johnson & Johnson here >>>)

Shares of Boeing have lost 2% in the past six months against the Zacks Aerospace & Defense industry’s rise of 7.3%. The Zacks analyst believes that Boeing is the largest aircraft manufacturer globally in terms of revenues, orders and deliveries, and one of the major aerospace and defense contractors.

Its revenue exposure is spread across more than 90 countries. Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes. Its proposed joint venture with Embraer is expected to strengthen its commercial business significantly.

However, the commercial business suffered a major setback due to lower 737 deliveries, following the 737 Max product line's grounding and subsequent costs associated with it. Consequently, its revenues, earnings and cash flow position were affected significantly.

(You can read the full research report on Boeing here >>>)

Pfizer’s shares have lost 15.6% over the past three months against the Zacks Large-Cap Pharmaceuticals industry’s rise of 0.5%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan (NASDAQ:MYL), if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz are top-line headwinds. Pfizer has a positive record of earnings surprises for recent quarters.

(You can read the full research report on Pfizer here >>>)

Other noteworthy reports we are featuring today include Qualcomm (QCOM), Petrobras (PBR) and Mitsubishi UFJ Financial (MUFG).

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.

See them now >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read
Featured Reports

Acquisitions Aid Mitsubishi UFJ (MUFG), High Expenses A Woe

Per the Zacks analyst, Mitsubishi UFJ has been growing through acquisitions and focus on its business upgradation plan (2018-2021).

Qualcomm (QCOM) Rides on Product Strength to Dissuade Rivals

Per the Zacks analyst, Qualcomm retains a competitive edge with several technological achievements, novel portfolio and 5G system level solutions across sub-6, gigahertz and millimeter wave bands.

Pre-Salt Reserves Boosts Petrobras (PBR), Debt Pile Hurts

Petrobras' interests in Brazil's attractive pre-salt oil reservoirs should boost its earnings outlook. However, the Zacks analyst is concerned over the company's huge debt load of nearly $83 billion.

Investments Aid Northrop (NOC), High Operating Expenses Hurt

Per the Zacks Analyst, Northrop Grumman (NYSE:NOC)'s regular investments in growth projects bolsters its future prospects.

EOG Resources (NYSE:EOG) Banks on Eagle Ford, Lease Expenses High

Huge inventory of premium drilling wells in the Eagle Ford shale will contribute to EOG Resources' oil production.

Steady Investments, Renewable Focus Aid Xcel Energy (NASDAQ:XEL)

Per the Zacks analyst, disciplined investments in infrastructure projects and focus on renewable generation as well as expansion will strengthen Xcel Energy's existing operations.

Rising Data-Center Demand Aids Digital Realty's (DLR) Growth

Per the Zacks Analyst, Digital Realty's accretive acquisitions and development efforts augur well amid pick-up in demand for data centers.

New Upgrades

Improving Retention Rate, Pay-TV Resizing Aids DISH (DISH)

Per the Zacks analyst, DISH's excellent customer service is improving retention. Also focus on acquiring and retaining subscribers that are profitable over the long term, is paying off.

Digital Investments & New Channels Aid Discovery (DISCA)

Per the Zacks analyst, the increased monetization of digital streaming products and new channel launches in several markets are expected to boost Discovery's growth.

Burlington Stores (BURL) Sturdy Comps Run to Propel Top-Line

Per the Zacks analyst, Burlington Stores' off-price model, comparable sales performance and growth strategies reinforce its position. Management expects third-quarter comparable sales growth of 2-3%.

New Downgrades

Crude Weakness, Downstream Woes to Weigh on Chevron (NYSE:CVX)

The Zacks analyst believes the sub-$55 oil price will make it difficult for Chevron to fund operations, making it dependent on asset sales. Weakness in its downstream unit is also a concern.

Hyatt's (H) Performance to be Hurt by Weakness in China

Per the Zacks analyst, lower demand in China and weakness in select business in the United States are likely to hurt Hyatt. Lingering political uncertainty in key operating regions remains a concern.

Freight Softness & Escalated Capex Ail Knight-Swift (KNX)

The Zacks analyst is worried about lackluster freight demand that is impeding Knight-Swift's growth. Moreover, high capital expenditures are denting the bottom line.


undefined undefined

QUALCOMM Incorporated (NASDAQ:QCOM): Free Stock Analysis Report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Petroleo Brasileiro S.A.- Petrobras (PBR): Free Stock Analysis Report

Mitsubishi UFJ Financial Group, Inc. (MUFG): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

The Boeing Company (NYSE:BA): Free Stock Analysis Report

Original post

Zacks Investment Research
Top Stock Reports For Johnson & Johnson, Boeing & Pfizer
 
Top Stock Reports For Johnson & Johnson, Boeing & Pfizer

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email